Folfox4 in Advanced Colorectal Cancer: A Monoinstitutional Experience-Reference-Cited by-同舟云学术

Folfox4 in Advanced Colorectal Cancer: A Monoinstitutional Experience

Published:2006-05 Issue:3 Volume:92 Page:193-196
ISSN:0300-8916
Container-title:Tumori Journal
language:en
Short-container-title:Tumori

Author:

Boscolo Giorgia¹,Pasetto Lara Maria¹,Jirillo Antonio¹,Monfardini Silvio¹

Affiliation:

1. Operative Unit of Medical Oncology, Istituto Oncologico Veneto, Padua, Italy

Abstract

Aims and background Patients included in clinical trials are “selected”, and they usually differ from those commonly treated. Methods: From 1999 to 2004, in the Medical Oncology Department of Padua (Italy), 70 metastatic colorectal cancers were treated with FOLFOX4. Results Our results, compared with those of the registration trial (response rate, duration of response and progression-free survival) appeared lower; overall survival was improved. Conclusions The number of therapeutic regimens more than their type influenced the results.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/030089160609200301

Reference8 articles.

1. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen

2. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

3. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

4. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

5. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.